Arkolith/Insider Trading/ADVM/Form 4

Soparkar Peter

CHIEF OPERATING OFFICERAdverum Biotechnologies, Inc. (ADVM) · full profile →Form 4 · filed Dec 10, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
4 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 9, 2025Tender(U)80K——0
Dec 9, 2025Tender(U)13K——0
Dec 9, 2025Tender(U)157K——0
Dec 9, 2025Grant(A)150K—$0157K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 9, 2025Disposed to issuer(D)45K——0
Dec 9, 2025Disposed to issuer(D)14K——0
Dec 9, 2025Disposed to issuer(D)39K——0
Dec 9, 2025Disposed to issuer(D)39K——0
Dec 9, 2025Disposed to issuer(D)40K——0
Dec 9, 2025Disposed to issuer(D)64K——0
Dec 9, 2025Disposed to issuer(D)79K——0
Dec 9, 2025Disposed to issuer(D)40K——0
Dec 9, 2025Disposed to issuer(D)16K——0
Dec 9, 2025Disposed to issuer(D)4K——0

Transaction Codes

U
See SEC Form 4 code table
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001736315-25-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML